Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)
VAUGHAN, ON and HEIDELBERG, Germany, July 7, 2022 — Bausch
investigational
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
NOV03 Met Primary Endpoints for Signs and Symptoms of Dry
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
NOV03 Met Both Primary Endpoints for Signs and Symptoms of
John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer
DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo